Starting Strength is the bestselling book on the most fundamental and effective approach to strength training ever written. Mark Rippetoe hosts Starting Strength Radio where he discusses topics of interest, primarily to him, but perhaps also to you.
…
continue reading
Content provided by humanOS Radio and Dan Pardi. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by humanOS Radio and Dan Pardi or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!
Go offline with the Player FM app!
#033 - Antibiotics Are Losing Efficacy, CRISPR May Save Us - Paul Garofolo, CEO Locus Bio
MP3•Episode home
Manage episode 202900308 series 1248550
Content provided by humanOS Radio and Dan Pardi. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by humanOS Radio and Dan Pardi or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
If you are alive today, you've benefited greatly from humankind's ability to deftly handle infectious agents via antibiotic medications. In fact, probably the single greatest achievement of modern medicine remains our ability to thwart (many) deadly microorganisms. But our high usage of antibiotics has put great pressure on these pathogenic bacteria to mutate for their own survival. As a result, deadly strains of bacteria have become more virulent and more resistant to our medications, creating so-called “superbugs.” For instance, an increasing percentage of tuberculosis cases worldwide are attributed to bacterial forms that are resistant to multiple drugs and require more complex treatments with an array of different medications. Eventually, former wonder drugs, like penicillin for instance, can be rendered ineffective. This is a very scary proposition and this problem is not likely to go away on its own. We need new ways to control bacterial infections and we need them fast. And that brings us to my guest today. In this episode of humanOS Radio, Dan speaks with Paul Garofolo. Paul is the CEO of Locus Biosciences, a biotech company that is developing a novel class of antimicrobials that take advantage of the CRISPR-Cas system. If this pans out, it would offer a viable alternative to conventional antibiotics, and would presumably be less subject to the known mechanisms of drug resistance. Secondly, this method could be targeted to specific pathogenic bacteria, thus leaving your friendly bugs alone. This seems like a win-win that is both lifesaving and health promoting, potentially (depending on the context).
…
continue reading
92 episodes
MP3•Episode home
Manage episode 202900308 series 1248550
Content provided by humanOS Radio and Dan Pardi. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by humanOS Radio and Dan Pardi or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
If you are alive today, you've benefited greatly from humankind's ability to deftly handle infectious agents via antibiotic medications. In fact, probably the single greatest achievement of modern medicine remains our ability to thwart (many) deadly microorganisms. But our high usage of antibiotics has put great pressure on these pathogenic bacteria to mutate for their own survival. As a result, deadly strains of bacteria have become more virulent and more resistant to our medications, creating so-called “superbugs.” For instance, an increasing percentage of tuberculosis cases worldwide are attributed to bacterial forms that are resistant to multiple drugs and require more complex treatments with an array of different medications. Eventually, former wonder drugs, like penicillin for instance, can be rendered ineffective. This is a very scary proposition and this problem is not likely to go away on its own. We need new ways to control bacterial infections and we need them fast. And that brings us to my guest today. In this episode of humanOS Radio, Dan speaks with Paul Garofolo. Paul is the CEO of Locus Biosciences, a biotech company that is developing a novel class of antimicrobials that take advantage of the CRISPR-Cas system. If this pans out, it would offer a viable alternative to conventional antibiotics, and would presumably be less subject to the known mechanisms of drug resistance. Secondly, this method could be targeted to specific pathogenic bacteria, thus leaving your friendly bugs alone. This seems like a win-win that is both lifesaving and health promoting, potentially (depending on the context).
…
continue reading
92 episodes
All episodes
×Welcome to Player FM!
Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.